Replies to post #312256 on Avid Bioservices Inc (CDMO)

[biopharm]

Justia Patents Ivana Türbachova Inventions, Patents and Patent Applications


Patents by Inventor Ivana Türbachova
Ivana Türbachova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Epigenetic Markers for the Identification of Blood Sub-cells of Type 1
Publication number: 20170233807
Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein said method comprises analysing the methylation status of at least one CpG position in the CD3a/b/c/d/g genes, in particular their “upstream” regulatory regions, and in particular the promoter and other conserved regions of the gene cd3, wherein a demethylation of at least one CpG in the analyzed sample to at least 90% is indicative for memory and naive CD4 or/and memory and/or naïve T lymphocytes. Furthermore, the present invention is directed at the use of DNA-methylation analysis of the genes CD3a/b/c/d for the detection and quality assurance and control of T lymphocytes. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof.
Type: Application
Filed: April 3, 2017
Publication date: August 17, 2017
Inventors: Sven OLEK, Ivana TÜRBACHOVA - deceased

After reading this patent more closely....this "upstream" looks like it could be referring to Phosphatidylserine and now more interesting is the Epiontis collaboration with Peregrine and Turbachova laboratory

[biopharm]

I still insist that patents that are filed as a result of collaborations with PS Targeting and learning new facts, new knowledge .....that IS NOT common knowledge ..etc etc may have to give some rights back to Peregrine and I hope Peregrine can see whom they gave PS Targeting info to and patents filed soon after must be monitored ...and questioned how such info would be known if it were not for PS Targeting knowledge and seeing which BIOMARKERS to concentrate on...etc

Precision For Medicine buys out Epiontis

Precision Medicine Group Raises $275M To Support Biomarker-Guided Drug Development
http://hitconsultant.net/2017/12/21/pmg-biomarker-guided-drug-development/

So tell me this... Epinotis and Precision For Medicine both working with Peregrine and Biomarkers must have been seen and Bird&Bird advised PFM to buy out Epiontis.....

So what Biomarkers were seen and by whom ?? Because Berkshire etc as of 5 days ago are now loading up close to $300M to back PFM next phase ....

Peregrine Board of Directors.....you guys just watching the ball drop tonight and best not be dropping the ball on seizing all that Biomarker data that was ONLY possible to be seen via PS Targeting

Happy New Year to Precision For Medicine and has Peregrine been analyzing all those Biomarkers ??

[biopharm]

Peregrine and Epiontis

Epiontis has Ulrich Hoffmueller with #1 collaborator Sven Olek
https://www.researchgate.net/profile/Ulrich_Hoffmueller

I still insist that patents that are filed as a result of collaborations with PS Targeting and learning new facts, new knowledge .....that IS NOT common knowledge ..etc etc may have to give some rights back to Peregrine and I hope Peregrine can see whom they gave PS Targeting info to and patents filed soon after must be monitored ...and questioned how such info would be known if it were not for PS Targeting knowledge and seeing which BIOMARKERS to concentrate on...etc

I am not saying this patent below falls into this but interesting filed April and published soon after....
_____________________

Epigenetic Markers for the Identification of Blood Sub-cells of Type 1
Publication number: 20170233807
Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein said method comprises analysing the methylation status of at least one CpG position in the CD3a/b/c/d/g genes, in particular their “upstream” regulatory regions, and in particular the promoter and other conserved regions of the gene cd3, wherein a demethylation of at least one CpG in the analyzed sample to at least 90% is indicative for memory and naive CD4 or/and memory and/or naïve T lymphocytes. Furthermore, the present invention is directed at the use of DNA-methylation analysis of the genes CD3a/b/c/d for the detection and quality assurance and control of T lymphocytes. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof.
Type: Application
Filed: April 3, 2017
Publication date: August 17, 2017
Inventors: Sven OLEK, Ivana TÜRBACHOVA - deceased

http://patents.justia.com/inventor/sven-olek

How can blood tests to detect cancer at early stages even be possible to use Biomarkers ...IF those Biomarkers are not known and the platformitude of data all basically originated and was confirmed on PS Targeting trials like Sunrise phase III ...??

What has Peregrine, now Avid Bioservices not informed shareholders about in regards to Biomarkers that were involved with collaborations with Epiontis and Precision For Medicine ?

Was the purchase by PFM of Epiontis a calculated move ....KNOWING they now possess new knowledge based upon Sunrise trial data which would help lay the foundation for further patents?? Besides that would Peter Thiel be of any relation to Andreas.

Andreas Thiel

Regenerative Immunology and Aging

Regenerative Immunology and Aging
Our work investigates changes in the immune system caused by the natural aging process, infections or diseases. Among other things, we are investigating the cellular and molecular mechanisms that cause the immune system to age. During aging, there are natural changes in the immune system, which make it susceptible to infection or cancer or reduce the vaccine protection. The responsible mechanisms for this diminished immunocompetence in old age are still not identified - this is where our multidisciplinary research comes in. Our current and future projects focus primarily on clinical immunology, immunomonitoring and cellular immunotherapy and diagnostics.

Our junior research group "T-cell immunity" is part of our work area. Marco Frentsch.

https://www.b-crt.de/forschung/forschungsfelder/immunsystem/regenerative-immunologie-und-altern/

Andreas Thiel above working with Epiontis Sven Olek but we are still back to how Bird&Bird advised Precision For Medicine to even buy out Epiontis ?

http://www.epiontis.com/about-epiontis/history.html